Using CRISPR/Cas9-mediated genome engineering in primary human fetal liver-derived HSCs and xenotransplantation in mice, researchers modeled GATA2-deficient myelodysplastic syndrome with acquired STAG2 loss to investigate disease initiation and progression. [Blood Advances] Abstract
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.